Investment Summary |
|
|---|---|
| Date | 2022-05-10 |
| Target | Formalogistics |
| Sector | Staffing |
| Investor(s) | Andera Partners |
| Deal Type | Stake Purchase |
SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 3.7B EUR |
| Size | Large |
| Type | Sector Agnostic |
Andera Partners is a private investment firm focused on several strategies. The Firm invests in life science opportunities through its BioDiscovery group. The Firm invests in Western European small to mid-sized companies (€30 to €300 million of revenue) through its Winch Capital group. Andera invests in small to mid-sized French companies (€10 to €100 million of revenue) through its Cabestan Capital team. Andera invests in €5 to €45 million of mezzanine capital to support small to mid-sized French companies. Andera Partners was established in 2001 and is headquartered in Paris.
| DEAL STATS | # |
|---|---|
| Overall | 101 of 106 |
| Sector: Staffing M&A | 2 of 2 |
| Type: Stake Purchase M&A Deals | 13 of 13 |
| Country: France M&A | 66 of 70 |
| Year: 2022 M&A | 8 of 11 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-05-03 |
Tubulis
Munich, Germany Tubulis generates uniquely matched antibody-drug conjugates (ADCs) through the combination of novel proprietary technologies and disease-specific biologic insight. Tubulis was founded in 2018 and is based in Munich, Germany. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-06-08 |
Mineralys
Radnor, Pennsylvania, United States Mineralys is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that the company is initially developing for the treatment of patients with uncontrolled hypertension. Mineralys was founded in 2019 and is based in Radnor, Pennsylvania. |
Buy | - |
